Greenleaf Trust’s Amedisys AMED Stock Holding History

Greenleaf Trust’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,345	Closed	-$232K	–	720
2022 Q1	$232K	Buy	+1,345	New	+$201K	﹤0.01%	680

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Greenleaf Trust's AMED Position: Q2 2022 in Review

Greenleaf Trust sold out of Amedisys (AMED) in Q2 2022, closing a stake of 1,345 shares — an estimated $232K sold.

Greenleaf Trust first reported a position in AMED in Q1 2022 and held it in 1 quarter. The position peaked at $232K in Q1 2022. 288 funds tracked by Wall St. Rank hold AMED as of Q2 2022.

Greenleaf Trust reported no remaining Amedisys position as of Q2 2022 after selling out during the quarter.
Greenleaf Trust sold 1,345 Amedisys shares in Q2 2022, an estimated $232K.
Greenleaf Trust first reported a position in Amedisys in Q1 2022 and held it in 1 quarter.
Greenleaf Trust's Amedisys position peaked at $232K in Q1 2022.
288 funds tracked by Wall St. Rank held Amedisys as of Q2 2022.

Based on Greenleaf Trust's 13F filing for Q2 2022, filed 12 Aug 2022.